| cCMV | congenital Cytomegalovirus |
| HCMV | human cytomegalovirus |
| PI | primary infection |
| T | transmitting women |
| NAb | neutralizing antibodies |
| NT | non-transmitting women |
| HIG | human immunoglobulin |
| gCs | glycoprotein complexes |
| PC | pentamer complex |
| mAbs | monoclonal antibodies |
| IMAB | inhibition of monoclonal antibody binding |
| PFI | plaque formation inhibition |
| LTI | leukocyte transfer inhibition |
| SFI | syncytium formation inhibition |
| ELISPOT assay | enzyme-linked immunospot assay |
| CID | cytomegalic inclusion disease |
| SNHL | sensoryneural hearing loss |
| TC | trimer complex |
| HPC | hemopoietic progenitor cells |
| EBV | Epstein-Barr virus |
| IE | immediate-early |
| UL | unique long region |
| BAC | bacterial artificial chromosome |
| US | unique short region |
| SNP | single nucleotide polymorphism |
| ADCC | antibody-dependent cellular cytotoxicity |
| ADCP | antibody-dependent cellular phagocytosis; |
| ADCD | antibody-dependent complement deposition |
| LPR | lymphoproliferative response |
| DB | dense bodies |
| MVA | modified vaccinia virus Ankara |
| SOT | solid-organ transplant |
| HSCT | hematopoietic stem cell transplant |
| CTB | cytotrophoblasts |
| STB | syncytiotrophoblasts |
| FV | floating villi |
| AV | anchoring villi |